January 16, 2025

New Publication: Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling

New Publication: Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling

Würth, R., Donato, E., Michel, L.L. et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling. Nat Cancer (2025). https://doi.org/10.1038/s43018-024-00882-2

Abstract

Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively study disease progression and therapy responses. Here we present the establishment of long-term CTC-derived organoids from female individuals with metastatic breast cancer. Multiomics analysis of CTC-derived organoids along with preclinical modeling with xenografts identified neuregulin 1 (NRG1)–ERBB2 receptor tyrosine kinase 3 (ERBB3/HER3) signaling as a key pathway required for CTC survival, growth and dissemination. Genome-wide CRISPR activation screens revealed that fibroblast growth factor receptor 1 (FGFR1) signaling serves a compensatory function to the NRG1–HER3 axis and rescues NRG1 deficiency in CTCs. Conversely, NRG1–HER3 activation induced resistance to FGFR1 inhibition, whereas combinatorial blockade impaired CTC growth. The dynamic interplay between NRG1–HER3 and FGFR1 signaling reveals the molecular basis of cancer cell plasticity and clinically relevant strategies to target it. Our CTC organoid platform enables the identification and validation of patient-specific vulnerabilities and represents an innovative tool for precision medicine.

Our latest News

discover more
TRANSVAC: a pillar of vaccine development in Europe for 16 years

TRANSVAC: a pillar of vaccine development in Europe for 16 years

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the EVI-led TRANSVAC project, an ambitious initiative funded by the European Commission. Since its launch in 2009, TRANSVAC has established itself as a key player in advancing vaccine research, supporting over 160 vaccine projects while fostering innovation and collaboration in […]

Novel analysis of intrinsically disordered proteins

Novel analysis of intrinsically disordered proteins

Researchers from Mainz University and EMBL Hamburg present a new approach for structurally characterising disordered proteins by combining two different analysis methods. Proteins are the molecules that perform most ‘actions’ in the cell, and thus, are key for our body functions. Essentially, proteins are strings of amino acids, which, in most cases, fold like origami […]

Repeated polyp diagnoses in relatives indicate higher risk of colorectal cancer

Repeated polyp diagnoses in relatives indicate higher risk of colorectal cancer

Researchers at the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have investigated the association between an individual’s risk of colorectal cancer and repeated diagnoses of colorectal polyp in relatives. They conclude that, in particular, the risk of developing colorectal cancer at a young age is significantly increased […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp